Key facts
- Infinity Bio’s last known valuation is $32.0M (Oct 2025).
- It has raised $12.5M across 3 recorded rounds; the latest was Early Stage VC ($5.0M) in Jun 2025.
- Notable investors include TEDCO, Illumina Ventures, Blackbird BioVentures, Blackbird Ventures (US), Johns Hopkins Technology Ventures — 7 tracked in total.
- Infinity Bio has filed 4 Form Ds with the SEC since 2023, most recently Aug 2025 ($5.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Infinity Bio
Funding rounds
3 roundsAbout Infinity Bio
Operator of an antibody profiling company intended to accelerate various discoveries. The company's platform utilizes libraries of proteins and peptides and a novel self-assembling system to comprehensively analyze an individual's antibody response, enabling researchers to understand the immune status of individuals or groups and identify immune-related patterns.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2023
- Employees
- 23
- Website
- infinitybio.com/
- Ownership
- Privately Held (backing)
Infinity Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Infinity Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Infinity Bio in its N-PORT filings yet. We sweep new filings monthly.